# Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

> **NCT05775159** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 294 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Biliary Tract Cancer

## Interventions

- **DRUG:** Volrustomig
- **DRUG:** Bevacizumab
- **DRUG:** Lenvatinib
- **DRUG:** Rilvegostomig
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05775159
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-24
- **Primary completion:** 2026-10-27
- **Final completion:** 2027-10-28
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775159, "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05775159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*